Journal of Clinical Oncology, Vol 15, 2518-2525, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein

H Yamauchi, A O'Neill, R Gelman, W Carney, DY Tenney, S Hosch and DF Hayes
Lombardi Cancer Center, Department of Medicine, Georgetown University Medical Center, Washington, DC, USA.

PURPOSE: Overexpression of the HER-2/c-neu/c-erbB2 proto-oncogene is associated with a worse prognosis in patients with breast cancer, perhaps due to an association of the HER-2 proto-oncogene protein with resistance to hormone and/or chemotherapy. Circulating levels of the extracellular domain (ECD) of the HER-2/c-neu-related protein (NRP) are elevated in 20% to 40% of patients with metastatic breast cancer. We investigated whether pretreatment levels of NRP predict response to hormone therapy (HT). MATERIALS AND METHODS: Circulating NRP levels were determined in 94 patients who participated in a randomized trial of three different doses of the antiestrogen, droloxifene (DRO), as first-line HT for metastatic breast cancer. RESULTS: NRP levels were elevated (> or = 5,000 U/mL) in 32 of 94 patients (34%). Only three of 32 patients (9%) with elevated NRP levels responded to DRO, compared with 35 of 62 (56%) with nonelevated NRP levels (P = .00001). Low pretreatment NRP level was the most powerful predictor of response to DRO (odds ratio of response, 22.4; P = .0001). Elevated pretreatment NRP levels were also associated with a shorter time to progression (TTP) and survival duration. CONCLUSION: Pretreatment circulating NRP levels predict a low likelihood of benefit from HT, specifically DRO, in patients with estrogen receptor (ER)-positive and/or progesterone receptor (PgR)-positive or receptor-unknown metastatic breast cancer, even when adjusted for other known predictive factors, such as ER and/or PgR levels, site of disease, disease-free interval from primary treatment to recurrence, and prior adjuvant chemotherapy. These data suggest that pretreatment NRP levels may be useful in deciding whether to treat a patient who otherwise appears to be likely to respond to HT.

This article has been cited by other articles:

				L. Harris, H. Fritsche, R. Mennel, L. Norton, P. Ravdin, S. Taube, M. R. Somerfield, D. F. Hayes, and R. C. Bast Jr American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer J. Clin. Oncol., November 20, 2007; 25(33): 5287 - 5312. [Abstract] [Full Text] [PDF]

				G. Guler, D. Iliopoulos, N. Guler, C. Himmetoglu, M. Hayran, and K. Huebner Wwox and Ap2{gamma} Expression Levels Predict Tamoxifen Response Clin. Cancer Res., October 15, 2007; 13(20): 6115 - 6121. [Abstract] [Full Text] [PDF]

				L. N. Harris, F. You, S. J. Schnitt, A. Witkiewicz, X. Lu, D. Sgroi, P. D. Ryan, S. E. Come, H. J. Burstein, B.-A. Lesnikoski, et al. Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer Clin. Cancer Res., February 15, 2007; 13(4): 1198 - 1207. [Abstract] [Full Text] [PDF]

				S. Massarweh and R. Schiff Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S15 - S24. [Abstract] [Full Text] [PDF]

				M. Dowsett, J. Houghton, C. Iden, J. Salter, J. Farndon, R. A'Hern, R. Sainsbury, and M. Baum Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status Ann. Onc., May 1, 2006; 17(5): 818 - 826. [Abstract] [Full Text] [PDF]

				M. De Laurentiis, G. Arpino, E. Massarelli, A. Ruggiero, C. Carlomagno, F. Ciardiello, G. Tortora, D. D'Agostino, F. Caputo, G. Cancello, et al. A Meta-Analysis on the Interaction between HER-2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer Clin. Cancer Res., July 1, 2005; 11(13): 4741 - 4748. [Abstract] [Full Text] [PDF]

				S. Tovey, B. Dunne, C. J. Witton, A. Forsyth, T. G. Cooke, and J. M.S. Bartlett Can Molecular Markers Predict When to Implement Treatment with Aromatase Inhibitors in Invasive Breast Cancer? Clin. Cancer Res., July 1, 2005; 11(13): 4835 - 4842. [Abstract] [Full Text] [PDF]

				B. Salvadori, P. Pinzani, V. Distante, D. Casella, S. Bianchi, M. Paglierani, V. Vezzosi, R. Neumann, L. Cataliotti, M. Pazzagli, et al. Comparison of Pre- and Postsurgical Concentrations of Blood HER-2 mRNA and HER-2 Extracellular Domain Reflects HER-2 Status in Early Breast Cancer Clin. Chem., January 1, 2005; 51(1): 254 - 256. [Full Text] [PDF]

				G. Arpino, S. J. Green, D. C. Allred, D. Lew, S. Martino, C. K. Osborne, and R. M. Elledge HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast Cancer: A Southwest Oncology Group Study Clin. Cancer Res., September 1, 2004; 10(17): 5670 - 5676. [Abstract] [Full Text] [PDF]

				L. Zhu, L. W. C. Chow, W. T. Y. Loo, X.-Y. Guan, and M. Toi Her2/neu Expression Predicts the Response to Antiaromatase Neoadjuvant Therapy in Primary Breast Cancer: Subgroup Analysis from Celecoxib Antiaromatase Neoadjuvant Trial Clin. Cancer Res., July 15, 2004; 10(14): 4639 - 4644. [Abstract] [Full Text] [PDF]

				J. S. Ross, J. A. Fletcher, K. J. Bloom, G. P. Linette, J. Stec, W. F. Symmans, L. Pusztai, and G. N. Hortobagyi Targeted Therapy in Breast Cancer: The HER-2/neu Gene and Protein Mol. Cell. Proteomics, April 1, 2004; 3(4): 379 - 398. [Abstract] [Full Text] [PDF]

				A. Argiris, C.-X. Wang, S. G. Whalen, and M. P. DiGiovanna Synergistic Interactions between Tamoxifen and Trastuzumab (Herceptin) Clin. Cancer Res., February 15, 2004; 10(4): 1409 - 1420. [Abstract] [Full Text] [PDF]

				R. Colomer, A. Llombart-Cussac, A. Lluch, A. Barnadas, B. Ojeda, V. Caranana, Y. Fernandez, J. Garcia-Conde, S. Alonso, S. Montero, et al. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain Ann. Onc., February 1, 2004; 15(2): 201 - 206. [Abstract] [Full Text] [PDF]

				A. Jones Combining trastuzumab (Herceptin(R)) with hormonal therapy in breast cancer: what can be expected and why? Ann. Onc., December 1, 2003; 14(12): 1697 - 1704. [Abstract] [Full Text] [PDF]

				W. P. Carney, R. Neumann, A. Lipton, K. Leitzel, S. Ali, and C. P. Price Potential Clinical Utility of Serum HER-2/neu Oncoprotein Concentrations in Patients with Breast Cancer Clin. Chem., October 1, 2003; 49(10): 1579 - 1598. [Abstract] [Full Text] [PDF]

				B. V. Jensen, J. S. Johansen, and P. A. Price High Levels of Serum HER-2/neu and YKL-40 Independently Reflect Aggressiveness of Metastatic Breast Cancer Clin. Cancer Res., October 1, 2003; 9(12): 4423 - 4434. [Abstract] [Full Text] [PDF]

				J. S. Ross, J. A. Fletcher, G. P. Linette, J. Stec, E. Clark, M. Ayers, W. F. Symmans, L. Pusztai, and K. J. Bloom The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy Oncologist, August 1, 2003; 8(4): 307 - 325. [Abstract] [Full Text] [PDF]

				R. Malayeri Can Endocrine Treatment for Hormone-Positive Premenopausal Women With Early Breast Cancer Replace Adjuvant Chemotherapy? J. Clin. Oncol., June 15, 2003; 21(12): 2444 - 2445. [Full Text] [PDF]

				S. De Placido, M. De Laurentiis, C. Carlomagno, C. Gallo, F. Perrone, S. Pepe, A. Ruggiero, A. Marinelli, C. Pagliarulo, L. Panico, et al. Twenty-year Results of the Naples GUN Randomized Trial: Predictive Factors of Adjuvant Tamoxifen Efficacy in Early Breast Cancer Clin. Cancer Res., March 1, 2003; 9(3): 1039 - 1046. [Abstract] [Full Text] [PDF]

				K. I. Pritchard, M. N. Levine, and D. Tu neu/erbB-2 Overexpression and Response to Hormonal Therapy in Premenopausal Women in the Adjuvant Breast Cancer Setting: Will It Play in Peoria? Part II J. Clin. Oncol., February 1, 2003; 21(3): 399 - 400. [Full Text] [PDF]

				G. Konecny, G. Pauletti, M. Pegram, M. Untch, S. Dandekar, Z. Aguilar, C. Wilson, H.-M. Rong, I. Bauerfeind, M. Felber, et al. Quantitative Association Between HER-2/neu and Steroid Hormone Receptors in Hormone Receptor-Positive Primary Breast Cancer J Natl Cancer Inst, January 15, 2003; 95(2): 142 - 153. [Abstract] [Full Text] [PDF]

				K. I. Pritchard Endocrine Therapy of Advanced Disease: Analysis and Implications of the Existing Data Clin. Cancer Res., January 1, 2003; 9(1): 460S - 467S. [Abstract] [Full Text] [PDF]

				T. Bachleitner-Hofmann, B. Pichler-Gebhard, M. Rudas, M. Gnant, S. Taucher, D. Kandioler, E. Janschek, P. Dubsky, S. Roka, E. Sporn, et al. Pattern of Hormone Receptor Status of Secondary Contralateral Breast Cancers in Patients Receiving Adjuvant Tamoxifen Clin. Cancer Res., November 1, 2002; 8(11): 3427 - 3432. [Abstract] [Full Text] [PDF]

				E. A. Perez, L. Geeraerts, V. J. Suman, A. A. Adjei, A. T. Baron, A. K. Hatfield, N. Maihle, J. C. Michalak, S. A. Kuross, J. W. Kugler, et al. A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer Ann. Onc., August 1, 2002; 13(8): 1225 - 1235. [Abstract] [Full Text] [PDF]

				S. M. Ali, K. Leitzel, V. M. Chinchilli, L. Engle, L. Demers, H. A. Harvey, W. Carney, J. W. Allard, and A. Lipton Relationship of Serum HER-2/neu and Serum CA 15-3 in Patients with Metastatic Breast Cancer Clin. Chem., August 1, 2002; 48(8): 1314 - 1320. [Abstract] [Full Text] [PDF]

				F. J. Esteva, V. Valero, D. Booser, L. T. Guerra, J. L. Murray, L. Pusztai, M. Cristofanilli, B. Arun, B. Esmaeli, H. A. Fritsche, et al. Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2-Overexpressing Metastatic Breast Cancer J. Clin. Oncol., April 1, 2002; 20(7): 1800 - 1808. [Abstract] [Full Text] [PDF]

				A. Lipton, S.M. Ali, K. Leitzel, L. Demers, V. Chinchilli, L. Engle, H. A. Harvey, C. Brady, C.M. Nalin, M. Dugan, et al. Elevated Serum HER-2/neu Level Predicts Decreased Response to Hormone Therapy in Metastatic Breast Cancer J. Clin. Oncol., March 15, 2002; 20(6): 1467 - 1472. [Abstract] [Full Text] [PDF]

				A. T. Baron, J. M. Lafky, V. J. Suman, D. W. Hillman, M. C. Buenafe, C. H. Boardman, K. C. Podratz, E. A. Perez, and N. J. Maihle A Preliminary Study of Serum Concentrations of Soluble Epidermal Growth Factor Receptor (sErbB1), Gonadotropins, and Steroid Hormones in Healthy Men and Women Cancer Epidemiol. Biomarkers Prev., November 1, 2001; 10(11): 1175 - 1185. [Abstract] [Full Text] [PDF]

				K. I. Pritchard Use of ErbB-1 and ErbB-2 to Select Endocrine Therapy for Breast Cancer: Will It Play in Peoria? J. Clin. Oncol., September 15, 2001; 19(18): 3795 - 3797. [Full Text] [PDF]

				M. J. Ellis, A. Coop, B. Singh, L. Mauriac, A. Llombert-Cussac, F. Janicke, W. R. Miller, D. B. Evans, M. Dugan, C. Brady, et al. Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1- and/or ErbB-2-Positive, Estrogen Receptor-Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial J. Clin. Oncol., September 15, 2001; 19(18): 3808 - 3816. [Abstract] [Full Text] [PDF]

				W. N. Hait The Prognostic and Predictive Values of ECD-HER-2 Clin. Cancer Res., September 1, 2001; 7(9): 2601 - 2604. [Abstract] [Full Text] [PDF]

				D. F. Hayes, H. Yamauchi, G. Broadwater, C. T. Cirrincione, S. P. Rodrigue, D. A. Berry, J. Younger, L. L. Panasci, F. Millard, D. B. Duggan, et al. Circulating HER-2/erbB-2/c-neu (HER-2) Extracellular Domain as a Prognostic Factor in Patients with Metastatic Breast Cancer: Cancer and Leukemia Group B Study 8662 Clin. Cancer Res., September 1, 2001; 7(9): 2703 - 2711. [Abstract] [Full Text] [PDF]

				A. S. Knoop, S. M. Bentzen, M. M. Nielsen, B. B. Rasmussen, and C. Rose Value of Epidermal Growth Factor Receptor, HER2, p53, and Steroid Receptors in Predicting the Efficacy of Tamoxifen in High-Risk Postmenopausal Breast Cancer Patients J. Clin. Oncol., July 15, 2001; 19(14): 3376 - 3384. [Abstract] [Full Text] [PDF]

				S. Kasimir-Bauer, S. Mayer, P. Bojko, D. Borquez, R. Neumann, and S. Seeber Survival of Tumor Cells in Stem Cell Preparations and Bone Marrow of Patients with High-Risk or Metastatic Breast Cancer after Receiving Dose-intensive or High-Dose Chemotherapy Clin. Cancer Res., June 1, 2001; 7(6): 1582 - 1589. [Abstract] [Full Text] [PDF]

				H. Yamauchi, V. Stearns, and D. F. Hayes When Is a Tumor Marker Ready for Prime Time? A Case Study of c-erbB-2 as a Predictive Factor in Breast Cancer J. Clin. Oncol., April 15, 2001; 19(8): 2334 - 2356. [Abstract] [Full Text] [PDF]

				L. N. Harris, V. Liotcheva, G. Broadwater, M. J. Ramirez, P. Maimonis, S. Anderson, T. Everett, D. Harpole, M. B. Moore, D. A. Berry, et al. Comparison of Methods of Measuring HER-2 in Metastatic Breast Cancer Patients Treated With High-Dose Chemotherapy J. Clin. Oncol., March 15, 2001; 19(6): 1698 - 1706. [Abstract] [Full Text] [PDF]

				R. C. Bast Jr, P. Ravdin, D. F. Hayes, S. Bates, H. Fritsche Jr, J. M. Jessup, N. Kemeny, G. Y. Locker, R. G. Mennel, and M. R. Somerfield 2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology J. Clin. Oncol., March 15, 2001; 19(6): 1865 - 1878. [Abstract] [Full Text] [PDF]

				R. Clarke, F. Leonessa, J. N. Welch, and T. C. Skaar Cellular and Molecular Pharmacology of Antiestrogen Action and Resistance Pharmacol. Rev., March 1, 2001; 53(1): 25 - 72. [Abstract] [Full Text] [PDF]

				D. A. Berry, H. B. Muss, A. D. Thor, L. Dressler, E. T. Liu, G. Broadwater, D. R. Budman, I. C. Henderson, M. Barcos, D. Hayes, et al. HER-2/neu and p53 Expression Versus Tamoxifen Resistance in Estrogen Receptor-Positive, Node-Positive Breast Cancer J. Clin. Oncol., October 20, 2000; 18(20): 3471 - 3479. [Abstract] [Full Text] [PDF]

				H. Kurokawa, A. E. G. Lenferink, J. F. Simpson, P. I. Pisacane, M. X. Sliwkowski, J. T. Forbes, and C. L. Arteaga Inhibition of HER2/neu (erbB-2) and Mitogen-activated Protein Kinases Enhances Tamoxifen Action against HER2-overexpressing, Tamoxifen-resistant Breast Cancer Cells Cancer Res., October 1, 2000; 60(20): 5887 - 5894. [Abstract] [Full Text]

				I. Kuter Breast Cancer Update Oncologist, August 1, 2000; 5(4): 285 - 292. [Abstract] [Full Text]

				R. E. Favoni and A. De Cupis The Role of Polypeptide Growth Factors in Human Carcinomas: New Targets for a Novel Pharmacological Approach Pharmacol. Rev., June 1, 2000; 52(2): 179 - 206. [Abstract] [Full Text] [PDF]

				R. Colomer, S. Montero, A. Lluch, B. Ojeda, A. Barnadas, A. Casado, B. Massutí, H. Cortés-Funes, and B. Lloveras Circulating HER2 Extracellular Domain and Resistance to Chemotherapy in Advanced Breast Cancer Clin. Cancer Res., June 1, 2000; 6(6): 2356 - 2362. [Abstract] [Full Text]

				R. C. Payne, J. W. Allard, L. Anderson-Mauser, J. D. Humphreys, D. Y. Tenney, and D. L. Morris Automated Assay for HER-2/neu in Serum Clin. Chem., February 1, 2000; 46(2): 175 - 182. [Abstract] [Full Text] [PDF]

				A. T. Baron, J. M. Lafky, C. H. Boardman, S. Balasubramaniam, V. J. Suman, K. C. Podratz, and N. J. Maihle Serum sErbB1 and Epidermal Growth Factor Levels As Tumor Biomarkers in Women with Stage III or IV Epithelial Ovarian Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 1999; 8(2): 129 - 137. [Abstract] [Full Text]

				H. Jinno, M. G. Steiner, R. G. Mehta, M. P. Osborne, and N. T. Telang Inhibition of aberrant proliferation and induction of apoptosis in HER-2/neu oncogene transformed human mammary epithelial cells by N-(4-hydroxyphenyl)retinamide Carcinogenesis, February 1, 1999; 20(2): 229 - 236. [Abstract] [Full Text] [PDF]

				J. S. Ross and J. A. Fletcher The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy Stem Cells, November 1, 1998; 16(6): 413 - 428. [Abstract] [Full Text]

				J. S. Ross and J. A. Fletcher The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy Oncologist, August 1, 1998; 3(4): 237 - 252. [Abstract] [Full Text]